NTRK Fusions

Identification of molecular alterations in NTRK 1-3 has become increasingly important with the emergence of histology-agnostic, US Food and Drug Administration-approved, effective inhibitors. The host discusses with Dr. Jaclyn Hechtman, director of clinical diagnostic development at Neogenomics, her practical insights on how testing for NTRK fusion can best be implemented and communicated within the multidisciplinary healthcare team.

Hosted on Acast. See acast.com/privacy for more information.

More from ModPath Chat

  1. 17:47Morphologic Feature Guiding Discovery of Driver Genetic Alteration in Rare EntityNov 24, 2022
  2. 25:54Risk Stratification for SLNB in MelanomaNov 10, 2022
  3. 29:59Flat urothelial lesions of the urinary bladder: Who is in who is out?Oct 27, 2022
  4. 17:54Radio-Resistant Prostate Carcinoma: “Cribriform” morphologies and DNA Damage Response and Repair defectsOct 13, 2022
  5. 17:58The Stanford Experience in Implementation of the Molecular Classification of Endometrial carcinomas (EC)Sep 29, 2022
  6. 21:19Expanding the clinico-pathological spectrum of SDH Deficient RCCSep 15, 2022
  7. 22:01High Risk and Selected Benign Breast Lesions on Core Biopsy: Excision Vs Surveillance?Sep 01, 2022
  8. 21:31Are ancillary studies of any utility in risk assessment of Barrett’s esophagus and dysplasia?Aug 18, 2022
  9. 17:55Ki-67 assessment in pancreatic neuroendocrine neoplasms manual vs. digital?Aug 04, 2022
  10. 15:21Heterogeneity of molecular alterations in CRC with peritoneal carcinomatosisJul 21, 2022